Expertise in
13
conditions

Dr. Giles W. Robinson

Hematology | Oncology
St. Jude Children's Research Hospital
262 Danny Thomas Pl, 
Memphis, TN 
Accepting New Patients
Expertise in
13
conditions
St. Jude Children's Research Hospital
262 Danny Thomas Pl, 
Memphis, TN 

Overview

Giles Robinson is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee.

Dr. Robinson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Rhabdoid Tumor.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 8 clinical trials. Dr. Robinson is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in CO

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D

Locations

St. Jude Children's Research Hospital
262 Danny Thomas Pl, Memphis, TN 38105

Additional Areas of Focus

Dr. Robinson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2026
Intervention Type: Procedure, Drug
Study Drug: Selumetinib
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine
Study Phase: Phase 2
St. Jude ELIOT: Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
St. Jude ELIOT: Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Biological, Drug
Study Drugs: Prexasertib, Cyclophosphamide, Gemcitabine, Filgrastim, Peg-filgrastim
Study Phase: Phase 1
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma
Enrollment Status: Completed
Publish Date: May 31, 2024
Intervention Type: Drug, Biological
Study Drugs: Gemcitabine, Ribociclib, Sonidegib, Trametinib, Filgrastim
Study Phase: Phase 1
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Enrollment Status: Completed
Publish Date: April 25, 2024
Intervention Type: Drug
Study Drug: LBH589
Study Phase: Phase 1
View 7 Less Clinical Trials

144 Total Publications

Global Burden of Pediatric Central Nervous System Tumors.
Global Burden of Pediatric Central Nervous System Tumors.
Journal: JAMA network open
Published: July 24, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Expertise in
18
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amar Gajjar is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Gajjar is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Posterior Fossa Tumor, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Decompression. Dr. Gajjar is currently accepting new patients.

Expertise in
7
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Expertise in
7
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-4153
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Hankins is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Hankins is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy. Dr. Hankins is currently accepting new patients.

Expertise in
16
conditions
Dr. Carlos A. Rodriguez-Galindo
Hematology | Oncology
Expertise in
16
conditions
Dr. Carlos A. Rodriguez-Galindo
Hematology | Oncology
Referral may be required

Office

262 Danny Thomas Pl # 515, 
Memphis, TN 
 (0.2 miles away)
901-595-3300
Languages Spoken:
English, Catalan, French, Spanish
See accepted insurances
Accepting New Patients

Carlos Rodriguez-Galindo is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Rodriguez-Galindo is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Germ Cell Tumor, Retinoblastoma, Langerhans Cell Histiocytosis, Hepatectomy, and Tissue Biopsy. Dr. Rodriguez-Galindo is currently accepting new patients.

Frequently Asked Questions about Dr. Giles W. Robinson

How do I make an appointment with Dr. Giles W. Robinson?

You can book an appointment with Dr. Giles W. Robinson by calling their office at 901-595-5175. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Giles W. Robinson a top-rated expert for Medulloblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Giles W. Robinson is classified as an Elite expert for Medulloblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Giles W. Robinson specialize in?

While Dr. Giles W. Robinson is a Hematology, they have specific expertise in Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Giles W. Robinson participate in research or clinical trials?

Yes. Dr. Giles W. Robinson has published 144 articles and abstracts on conditions like Medulloblastoma. You can view a list of Dr. Giles W. Robinson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Giles W. Robinson accept my insurance?

Dr. Giles W. Robinson accepts most major insurance plans, including Blue Cross Blue Shield and Quartz Health Plan. We recommend calling the office directly at 901-595-5175 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robinson's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile